SCHEMBL1649706

SCHEMBL1649706

[CH2]C#CCN(CC)CC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10257125 0.81 CHRM2 (0.59)
SCHEMBL966552 0.75
SCHEMBL7914134 0.74
SCHEMBL936173 0.73
SCHEMBL937076 0.73 CHRM2 (0.52)
SCHEMBL3989603 0.71
SCHEMBL30902061 0.71 CHRM2 (0.50)
SCHEMBL11061058 0.69 CHRM1 (0.48)
SCHEMBL3362784 0.69 CHRM2 (0.48)
SCHEMBL135037 0.69 CHRM1 (0.54)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 EP claimed
US-20120294938-A1 PHARMACEUTICAL PREPARATION FOR ORAL ADMINISTRATION WITH CONTROLLED ACTIVE INGREDIENT RELEASE IN THE SMALL INTESTINE AND METHOD FOR ITS PRODUCTION Dr. R. Pflefger Chemische Fabrik GmbH (DE) 2012-11-22 US claimed
US-7846959-B2 Raf modulators and methods of use EXELIXIS, INC. (US) 2010-12-07 US claimed
US-20090285891-A1 Pharmaceutical preparation for oral administration with controlled active ingredient release in the small intestine and method for its production DR. R. PFLEGER CHEMISCHE FABRIK GMBH (DE) 2009-11-19 US claimed
EP-2101759-A1 METHODS OF USING MEK INHIBITORS Exelixis, Inc. (US) 2009-09-23 EP claimed
WO-2009017838-A2 COMBINATIONS OF JAK-2 INHIBITORS AND OTHER AGENTS EXELIXIS, INC. (US) 2009-02-05 WO claimed
WO-2008076415-A1 METHODS OF USING MEK INHIBITORS EXELIXIS, INC. (US) 2008-06-26 WO claimed
US-20080009488-A1 Raf Modulators and Methods of Use EXELIXIS, INC. (US) 2008-01-10 US claimed
US-20060188554-A1 Transdermal absorption preparation KYORIN PHARMACEUTICAL CO., LTD. (JP) 2006-08-24 US claimed
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 EP disclosed
US-8697737-B2 Raf modulators and methods of use EXELIXIS, INC. (US) 2014-04-15 US disclosed
US-20120294938-A1 PHARMACEUTICAL PREPARATION FOR ORAL ADMINISTRATION WITH CONTROLLED ACTIVE INGREDIENT RELEASE IN THE SMALL INTESTINE AND METHOD FOR ITS PRODUCTION Dr. R. Pflefger Chemische Fabrik GmbH (DE) 2012-11-22 US disclosed
US-8221787-B2 Pharmaceutical preparation for oral administration with controlled active ingredient release in the small intestine and method for its production Dr. Robert Pfleger Chemische Fabrik GmbH (DE) 2012-07-17 US disclosed
US-7927613-B2 Pharmaceutical co-crystal compositions UNIVERSITY OF SOUTH FLORIDA (US) 2011-04-19 US disclosed
WO-2004039763-A1 QUATERNARY AMMONIUM COMPOUNDS PHARMACIA & UPJOHN COMPANY LLC (US) 2004-05-13 WO disclosed
JP-2001048783-A PERCUTANEOUSLY ABSORBABLE TYPE THERAPEUTIC AGENT FOR POLLAKIURIA AND INCONTINENCE OF URINE LEAD CHEMICAL CO LTD 2001-02-20 JP disclosed
US-5719155-A CARDIOVASCULAR DISORDERS JAPAN TOBACCO INC. (JP) 1998-02-17 US disclosed
EP-0677519-A1 CHROMAN DERIVATIVE AND MEDICINAL USE THEREOF Japan Tobacco Inc. (JP) 1995-10-18 EP disclosed
EP-0250125-B1 DRUG DELIVERY DEVICE, ITS PREPARATION AND USE Smith &amp; Nephew plc (GB) 1991-09-18 EP disclosed
US-4784857-A Drug delivery device, its preparation and use SMITH AND NEPHEW ASSOCIATED COMPANIES PLC (GB) 1988-11-15 US disclosed